Immunotoxins containing Pseudomonas exotoxin A: a short history.
作者信息
Pastan Ira
机构信息
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 5106, Bethesda, MD 20892-4268, USA.
出版信息
Cancer Immunol Immunother. 2003 May;52(5):338-41. doi: 10.1007/s00262-002-0353-8. Epub 2003 Mar 6.
Abstract
摘要
相似文献
1
Immunotoxins containing Pseudomonas exotoxin A: a short history.
Cancer Immunol Immunother. 2003 May;52(5):338-41. doi: 10.1007/s00262-002-0353-8. Epub 2003 Mar 6.
2
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2.
3
Mechanisms of Resistance to Immunotoxins Containing Exotoxin A in Cancer Therapy.
Biomolecules. 2020 Jun 30;10(7):979. doi: 10.3390/biom10070979.
4
Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Hum Vaccin. 2007 Mar-Apr;3(2):39-40; author reply 41. doi: 10.4161/hv.3.2.3715. Epub 2007 Mar 8.
5
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
J Immunol Methods. 2011 Aug 31;371(1-2):122-33. doi: 10.1016/j.jim.2011.06.023. Epub 2011 Jun 30.
6
Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Bull Exp Biol Med. 2013 Jan;154(3):346-50. doi: 10.1007/s10517-013-1947-1.
7
Immunogenicity of Immunotoxins Containing Exotoxin A: Causes, Consequences, and Mitigation.
Front Immunol. 2020 Jun 26;11:1261. doi: 10.3389/fimmu.2020.01261. eCollection 2020.
8
Immunogenicity of therapeutic recombinant immunotoxins.
Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390.
9
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
J Immunol. 2006 Dec 15;177(12):8822-34. doi: 10.4049/jimmunol.177.12.8822.
10
HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
Biochem Biophys Res Commun. 2016 Jun 17;475(1):93-9. doi: 10.1016/j.bbrc.2016.05.044. Epub 2016 May 10.
引用本文的文献
1
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
Oncotarget. 2019 Jan 25;10(8):897-915. doi: 10.18632/oncotarget.26618.
2
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.
Am J Pathol. 2018 Aug;188(8):1736-1743. doi: 10.1016/j.ajpath.2018.04.016. Epub 2018 Jun 2.
3
Evaluation of Vegf-Pseudomonas Exotoxin: A Conjugated on Tumor Cells.
Adv Biomed Res. 2017 Nov 20;6:144. doi: 10.4103/2277-9175.218691. eCollection 2017.
4
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.
Biomedicines. 2017 Feb 17;5(1):9. doi: 10.3390/biomedicines5010009.
5
Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin.
Biotechnol Prog. 2014 Nov-Dec;30(6):1380-9. doi: 10.1002/btpr.1983. Epub 2014 Sep 2.
6
Novel bacterial ADP-ribosylating toxins: structure and function.
Nat Rev Microbiol. 2014 Sep;12(9):599-611. doi: 10.1038/nrmicro3310. Epub 2014 Jul 14.
7
An update in the use of antibodies to treat glioblastoma multiforme.
Autoimmune Dis. 2013;2013:716813. doi: 10.1155/2013/716813. Epub 2013 Nov 5.
8
Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary.
PLoS One. 2012;7(10):e47320. doi: 10.1371/journal.pone.0047320. Epub 2012 Oct 9.
9
In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.
Oncol Lett. 2012 Aug;4(2):311-318. doi: 10.3892/ol.2012.733. Epub 2012 May 25.
10
Targeting malignant B cells with an immunotoxin against ROR1.
MAbs. 2012 May-Jun;4(3):349-61. doi: 10.4161/mabs.19870. Epub 2012 Apr 26.
Zotero 插件